61-LB: Continuous Glucose Monitoring (CGM) in ICU Patients during COVID-19: A Pilot Study

Abstract

Objective: During the COVID 19 pandemic, the FDA approved emergency authorization of Real Time Continuous Glucose Monitoring (RT-CGM) for inpatient use. The objective of this study was to evaluate the safety of RT-CGM use. Methods: Blood Glucose (BG) data were collected from the electronic medical record and the Dexcom system on 165 patients treated on DEXCOM CGM from June to December using a preapproved protocol. Retrospective chart review was performed on 60 patients on vasopressors and dialysis. Analysis included glycemic control, hypoglycemia rate, and correlation between finger stick (FS) and RT-CGM BG. Pearson's correlation coefficients (PCC) and MARD were calculated. Strong correlation was defined as a PCC value of > 0.7. Results: Of the > 300,000 BG readings from DEXCOM, 81 % were between 70-180 mg/dl;12 % between 180-250mg/dl;and 5% were > 250 mg/dl. The incidence of hypoglycemia was low, 0.8% values being between 55 - 69 mg/dL and 0.5% being < 55 mg/dL. Of the 2016 readings used for correlation, the PCC between FS and RT-CGM glucose was 0.838 with a MARD of 14%. PCC was 0.798 for patients on vasopressors and 0.79 for dialysis Patients. Conclusions: In this preliminary study, Dexcom CGM utilization was safe with a low incidence of hypoglycemia and good correlation to FS blood glucose. CGM utilization decreased the frequency of FS for most patients, and was well accepted by the clinical team.